Una composicion farmacéutica que comprende un derivado de pirazol-O-glucosido, combinado con un inhibidor de DPP IV en el tratamiento o la prevencion de una o más afecciones seleccionadas entre la diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, tolerancia anormal a la glucosa e hiperglucemia. Métodos para prevenir o tratar trastornos metabolicos y afecciones relacionadas. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende un derivado de pirazol-O-glucosido de la formula (1) en donde R1 denota alcoxi C1-3; L1, L2, independientemente uno del otro, denota H o F; R6 denota H, (alquil C1-3)carbonilo, (alquil C1-6)oxicarbonilo, feniloxicarbonilo, benciloxicarbonilo o bencilcarbonilo, combinado con un inhibidor de DPP IV de formula (2) a formula (5), en donde R1 denota ([1,5]naftiridin-2-il)metilo, (quinazolin-2-iI)metilo, (quinoxalin-6-il)metilo, (4-metil-quinazolin-2-iI)metilo, 2-ciano-bencilo, (3-ciano-quinolin-2-ilmetiIo, (3-ciano-piridin-2-il)metilo, (4-metil-pirimidin-2-iI)metilo o (4,6-dimetil-pirimidin-2-il)metilo y R2 denota 3-(R)-amino-piperidin-1-ilo, (2-amino-2-metil-propil)-metilamino o (2-(S)-amino-propil)-metilamino, o su sal farmacéuticamente aceptable. Reivindicacion 2: La composicion farmacéutica segun la reivindicacion 1 caracterizada porque el derivado de pirazol-O-glucosido se selecciona del grupo de compuestos (i) a (xiv): (i) 4-(2,3-difluoro-4-metoxibencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (ii) 4-(2,5-difluoro-4-metoxibencil)-1-isopropil-5-metil-3-b-D-gIucopiranos-1-iloxi-1H-pirazol; (iii) 4-(2,6-difluoro-4-metoxibencil)-1-isopropiI-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (iv) 4-(3,5-difluoro-4-metoxibencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (v) 4-(3-fluoro-4-etoxibencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (vi) 4-(3-fluoro-4-isopropoxibencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (vii) 4-(2-fluoro-4-metoxibencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (viii) 4-(2-fluoro-4-isopropoxibencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (ix) 4-(2-fluoro-4-etoxibencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (x) 4-(2,3-difluoro-4-isopropoxibencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (xi) 4-(3-fluoro-4-metoxibencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (xii) 4-(4-metoxi-bencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (xiii) 4-(4-etoxi-bencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; (xiv) 4-(4-isopropoxi-bencil)-1-isopropil-5-metil-3-b-D-glucopiranos-1-iloxi-1H-pirazol; y aquellos derivados de los compuestos (i) a (xiv) en los que el átomo H del grupo HO unido al átomo de carbono en la 6ta posicion del grupo b-D-glucopiranosilo se reemplaza con un sustituyente seleccionado entre (alquil C1-3)carbonilo y (alquil C1-4)oxicarbonilo. Reivindicacion 3: La composicion farmacéutica segun la reivindicacion 1 o 2, caracterizada porque el inhibidor de DPP IV se selecciona entre el grupo que consiste en: 1-[(4-metil-quinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(R)-amino-piperidin-1-il)-xantina, 1-[([1,5]naftiridin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-((R)-3-amino-piperidin-1-il)-xantina, 1-[(quinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-((R)-3-amino-piperidin-1-il)-xantina, 2-((R)-3-amino-piperidin-1-il)-3-(but-2-iniI)-5-(4-metil-quinazolin-2-ilmetil)-3,5-dihidro-imidazo[4,5-d]piridazin-4-ona, 1-[(4-metil-quinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-[(2-amino-2-metil-propil)-metilamino]-xantina, 1-[(3-ciano-quinolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-((R)-3-amino-piperidin-1-il)-xantina, 1-(2-ciano-bencil)-3-metil-7-(2-butin-1-il)-8-((R)-3-amino-piperidin-1-il)-xantina, 1-[(4-metil-quinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-[(S)-(2-amino-propil)-metilamino]-xantina, 1-[(3-ciano-piridin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-((R)-3-amino-piperidin-1-il)-xantina, 1-[(4-metil-pirimidin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-((R)-3-amino-piperidin-1-il)-xantina, 1-[(4,6-dimetil-pirimidin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-((R)-3-amino-piperidin-1-il)-xantina, y 1-[(quinazolin-6-il)metil]-3-metil-7-(2-butin-1-il)-8-((R)-3-amino-piperidin-1-il)-xantina, o una sal farmacéuticamente aceptable de los mismos.A pharmaceutical composition comprising a pyrazole-O-glucoside derivative, combined with a DPP IV inhibitor in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, abnormal tolerance to glucose and hyperglycemia. Methods to prevent or treat metabolic disorders and related conditions. Claim 1: A pharmaceutical composition characterized in that it comprises a pyrazole-O-glucoside derivative of the formula (1) wherein R1 denotes C1-3 alkoxy; L1, L2, independently of each other, denotes H or F; R6 denotes H, (C1-3 alkyl) carbonyl, (C1-6 alkyl) oxycarbonyl, phenyloxycarbonyl, benzyloxycarbonyl or benzylcarbonyl, combined with a DPP IV inhibitor of formula (2) to formula (5), wherein R1 denotes ([ 1,5] naphthyridin-2-yl) methyl, (quinazolin-2-iI) methyl, (quinoxalin-6-yl) methyl, (4-methyl-quinazolin-2-iI) methyl, 2-cyano-benzyl, ( 3-Cyano-quinolin-2-ylmethIo, (3-cyano-pyridin-2-yl) methyl, (4-methyl-pyrimidin-2-iI) methyl or (4,6-dimethyl-pyrimidin-2-yl) methyl and R2 denotes 3- (R) -amino-piperidin-1-yl, (2-amino-2-methyl-propyl) -methylamino or (2- (S) -amino-propyl) -methylamino, or its pharmaceutically acceptable salt Claim 2: The pharmaceutical composition according to claim 1 characterized in that the pyrazole-O-glucoside derivative is selected from the group of compounds (i) to (xiv): (i) 4- (2,3-difluoro-4-methoxybenzyl) ) -1-isopropyl-5-methyl-3-bD-glucopyranos-1-yloxy-1H-pyrazole; (ii) 4- (2,5-difluoro-4-methoxybenzyl) -1-isopropyl-5-methyl-3 -bD-gIucopyranos-1-yloxy-1H-pyrazole; (iii) 4- (2,6- difluoro-4-methoxybenzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranoses-1-yloxy-1H-pyrazole; (iv) 4- (3,5-Difluoro-4-methoxybenzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; (v) 4- (3-Fluoro-4-ethoxybenzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; (vi) 4- (3-Fluoro-4-isopropoxybenzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; (vii) 4- (2-Fluoro-4-methoxybenzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; (viii) 4- (2-fluoro-4-isopropoxybenzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; (ix) 4- (2-Fluoro-4-ethoxybenzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; (x) 4- (2,3-Difluoro-4-isopropoxybenzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; (xi) 4- (3-fluoro-4-methoxybenzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; (xii) 4- (4-methoxy-benzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranoses-1-yloxy-1H-pyrazole; (xiii) 4- (4-ethoxy-benzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; (xiv) 4- (4-isopropoxy-benzyl) -1-isopropyl-5-methyl-3-b-D-glucopyranos-1-yloxy-1H-pyrazole; and those derived from compounds (i) to (xiv) in which the H atom of the HO group attached to the carbon atom in the 6th position of the bD-glucopyranosyl group is replaced with a substituent selected from (C1-3 alkyl) carbonyl and (C1-4 alkyl) oxycarbonyl. Claim 3: The pharmaceutical composition according to claim 1 or 2, characterized in that the DPP IV inhibitor is selected from the group consisting of: 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl- 7- (2-butin-1-yl) -8- (3- (R) -amino-piperidin-1-yl) -xanthine, 1 - [([1,5] naphthyridin-2-yl) methyl] - 3-methyl-7- (2-butin-1-yl) -8 - ((R) -3-amino-piperidin-1-yl) -xanthine, 1 - [(quinazolin-2-yl) methyl] -3 -methyl-7- (2-butin-1-yl) -8 - ((R) -3-amino-piperidin-1-yl) -xanthine, 2 - ((R) -3-amino-piperidin-1- il) -3- (but-2-iniI) -5- (4-methyl-quinazolin-2-ylmethyl) -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one, 1- [ (4-methyl-quinazolin-2-yl) methyl] -3-methyl-7- (2-butin-1-yl) -8 - [(2-amino-2-methyl-propyl) -methylamino] -xanthine, 1 - [(3-cyano-quinolin-2-yl) methyl] -3-methyl-7- (2-butin-1-yl) -8 - ((R) -3-amino-piperidin-1-yl) -xanthine, 1- (2-cyano-benzyl) -3-methyl-7- (2-butin-1-yl) -8 - ((R) -3-amino-piperidin-1-yl) -xanthine, 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl-7- (2-butin-1-yl) -8 - [(S) - (2-amino-propyl) -methylamino] - xanthine, 1 - [(3-cyano-pyridin-2-yl) methyl] -3-methyl-7- (2-butin-1-yl) -8 - ((R) -3-amino-piperidin-1-yl) -xanthine, 1 - [(4-methyl-pyrimidin-2 -yl) methyl] -3-methyl-7- (2-butin-1-yl) -8 - ((R) -3-amino-piperidin-1-yl) -xanthine, 1 - [(4,6- dimethyl-pyrimidin-2-yl) methyl] -3-methyl-7- (2-butin-1-yl) -8 - ((R) -3-amino-piperidin-1-yl) -xanthine, and 1- [(quinazolin-6-yl) methyl] -3-methyl-7- (2-butin-1-yl) -8 - ((R) -3-amino-piperidin-1-yl) -xanthine, or a salt pharmaceutically acceptable thereof.